FILTER

FILTERED INTERVIEW RESULTS

Jeffrey Nau

PRESIDENT & CEO, OYSTER POINT PHARMA
"Our mission is to bring novel and transformative therapies to the anterior (front) chamber of the eye, particularly for the treatment of ocular surface disease."

Shuang Liu

CEO & FOUNDER, CONSYNANCE THERAPEUTICS
"Although each rare disease impacts a small population, the rare disease population is estimated to be 10% of the total population, meaning 25-30 million Americans have at least one rare condition."

Jay Roberts & Robert Fremeau

PRESIDENT AND CEO & CHIEF SCIENTIFIC OFFICER, VYANT BIO
"At Vyant Bio we are reinventing how drugs are discovered for complex neurological and neurodegenerative disorders by applying a human-first approach."

Andrea Pfeifer

CO-FOUNDER & CEO, AC IMMUNE
"AC Immune is combining diagnostics and therapeutics, and it has developed the tools to enable detection and clearance of specific pathological proteins underlying neurodegenerative diseases."

Trevor P. Castor

PRESIDENT & CEO, APHIOS CORPORATION
"In 2021, we focused on introducing our green pathogen reduction technology to biotechnology and pharmaceutical companies."

Jeff Butler

PRESIDENT, AMPAC FINE CHEMICALS, AN SK PHARMTECO COMPANY
"Outside of our manufacturing capabilities, AFC is investing and featuring AMPAC Analytical given the growing demand for pharmaceutical testing services."

Louis Kassa

PRESIDENT & CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"Our blueprint to success has manifested in six IPOs and over US$3 billion worth of company value created."

Jan Kengelbach

CEO, AENOVA GROUP
"While it's always easier to deny a certain service if you don't yet have the technical expertise in a particular area, in the long-term it is advantageous to explore the possibility of investing in that area with the customer."

Russell Trenary

PRESIDENT & CEO, OUTLOOK THERAPEUTICS
"If our ophthalmic bevacizumab is approved, we will potentially enhance the standard of care for patients with disorders like wet AMD, diabetic macular edema, and branch retinal vein occlusion by removing concerns related to off-label repackaged IV product."

Albert Friesen

CEO & CHAIRMAN OF THE BOARD, MEDICURE INC.
"Our recently launched e-commerce site for Marley Drug has huge potential and will be our most significant driver of growth and major source of our profits moving forward."

MACIG

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

Singapore Chemicals 2022 IHS CW Release

PARTNER EVENTS